title: Detection of CD55 and/or CD59 deficient red cell populations in patients with aplastic anaemia, myelodysplastic syndromes and myeloproliferative disorders.
abstract: Paroxysmal nocturnal haemoglobinuria (PNH) is an acquired clonal stem cell disorder characterized by intravascular haemolysis, venous thrombosis, marrow hypoplasia, frequent episodes of infection, and rarely leukaemic conversion. At the cellular level, PNH is characterized by the decrease or absence of glycosylphosphatidylinositol (GPI)-anchored molecules, such as CD55 and CD59, from the cell surface. PNH-like clones have been described in various haematological disorders. The link between PNH and aplastic anaemia (AA) has been established but the relationship of PNH with myelodysplastic syndromes (MDS) or myeloproliferative disorders (MPD) remains unclear. In this study, the presence of CD55 and/or CD59 defective (PNH-like) red cell populations was evaluated in 21 patients with AA, 133 with MDS, 197 with MPD, 7 with PNH and in 121 healthy blood donors using the Sephacryl Gel Test microtyping system. Red cell populations deficient in both molecules CD55 and CD59 were detected in 33.3% of AA patients, in 16.5% of MDS patients (50% with hypoplastic bone marrow), in 14.2% of MPD patients (more often in essential thrombocythemia, 21.2%) and in all PNH patients. CD55 deficient red cell populations were found in 14.2% of patients with AA, 12.7% of patients with MDS and 21.3% of patients with MPD. CD59 deficient populations were found in 9.5% of AA patients, 2.2% of MDS patients and 2% of MPD patients. These results indicate an association between PNH, AA and MDS or even between PNH and MPD. Further investigation is necessary to work out the mechanisms of this association, and to define classification criteria for borderline cases, where diagnosis is difficult.
authors.affiliation: First Department of Internal Medicine, University of Athens School of Medicine, Laiko General Hospital, Greece. imeletis@cc.uoa.gr
authors.forename: J
authors.initials: J
authors.lastname: Meletis
authors.forename: E
authors.initials: E
authors.lastname: Terpos
authors.forename: M
authors.initials: M
authors.lastname: Samarkos
authors.forename: C
authors.initials: C
authors.lastname: Meletis
authors.forename: K
authors.initials: K
authors.lastname: Konstantopoulos
authors.forename: V
authors.initials: V
authors.lastname: Komninaka
authors.forename: E
authors.initials: E
authors.lastname: Apostolidou
authors.forename: O
authors.initials: O
authors.lastname: Benopoulou
authors.forename: K
authors.initials: K
authors.lastname: Korovesis
authors.forename: D
authors.initials: D
authors.lastname: Mavrogianni
authors.forename: E
authors.initials: E
authors.lastname: Variami
authors.forename: X
authors.initials: X
authors.lastname: Yataganas
authors.forename: D
authors.initials: D
authors.lastname: Loukopoulos
mesh_terms: D000741:Anemia, Aplastic / Q000097:blood / Q000276:immunology* / Q000473:pathology; D018958:CD55 Antigens / Q000276:immunology; D018957:CD59 Antigens / Q000276:immunology; D004906:Erythrocyte Count; D004912:Erythrocytes / Q000276:immunology* / Q000473:pathology; D006801:Humans; D016130:Immunophenotyping; D009190:Myelodysplastic Syndromes / Q000097:blood / Q000276:immunology* / Q000473:pathology; D009196:Myeloproliferative Disorders / Q000097:blood / Q000276:immunology* / Q000473:pathology
chemical_list: D018958:CD55 Antigens; D018957:CD59 Antigens